专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08841426B2 Mutant of granulocyte-colony stimulating factor (G-CSF) and chemically conjugated polypeptide thereof 有权
标题翻译：粒细胞集落刺激因子（G-CSF）突变体及其化学结合多肽
公开(公告)号：US08841426B2
公开(公告)日：2014-09-23
申请号：US11995968
申请日：2006-07-19
申请人： Kwan-Yub Kang , Jeong-Woon Hong
发明人： Kwan-Yub Kang , Jeong-Woon Hong
IPC分类号： A61K38/24 , C07K1/00 , C07K14/535 , A61K47/48
CPC分类号： C07K14/535 , A61K47/60
摘要： Provided are mutants of human granulocyte-colony stimulating factor (G-CSF) designed for specific chemical conjugation, and chemical conjugates thereof for use as an adjuvant in the treatment of cancer. The present invention provides a mutant of a G-CSF in which a threonine (Thr) residue at position 133 of G-CSF comprising the amino acid sequence identified in SEQ ID NO: 1 is substituted with a cysteine (Cys) residue. In addition, the invention provides a mutant of a G-CSF in which a cysteine (Cys) residue is inserted between a glycine (GIy) residue at position 135 and an alanine (Ala) residue at position 136 of G-CSF. Further, the invention provides a chemically conjugated mutant G-CSF to which biocompatible polymer such as polyethylene glycol (PEG) was attached at the cysteine residue, which was introduced by the substitution or insertion mutation, increasing its in vivo retention time without reducing in vivo biological activity due to the conjugation with the biocompatible polymer, thereby ultimately extending the in vivo biological activity.
摘要翻译：提供设计用于特定化学共轭的人粒细胞集落刺激因子（G-CSF）的突变体，以及用作癌症治疗中的佐剂的化学共轭物。本发明提供了G-CSF的突变体，其中包含SEQ ID NO：1中鉴定的氨基酸序列的G-CSF的第133位的苏氨酸（Thr）残基被半胱氨酸（Cys）残基取代。此外，本发明提供了G-CSF的突变体，其中将半胱氨酸（Cys）残基插入在135位的甘氨酸（Gly）残基和G-CSF的第136位的丙氨酸（Ala）残基之间。此外，本发明提供了在半胱氨酸残基处连接生物相容性聚合物如聚乙二醇（PEG）的化学偶联的突变体G-CSF，其通过取代或插入突变引入，增加其体内保留时间而不降低体内由于与生物相容性聚合物共轭而产生的生物活性，从而最终延长了体内的生物活性。

2. 发明授权

US08715696B2 Full genome DNA of human cytomegalovirus strain JHC isolated from Korean patient and open reading frames thereof 有权
标题翻译：从韩国患者分离的人巨细胞病毒株JHC的全基因组DNA和其开放阅读框
公开(公告)号：US08715696B2
公开(公告)日：2014-05-06
申请号：US13306080
申请日：2011-11-29
申请人： Chan Hee Lee
发明人： Chan Hee Lee
IPC分类号： A61K39/25 , A61K39/245 , A01N63/00 , A01N65/00 , C12N7/00 , C12N7/01 , A61K39/00 , A61K39/38 , C12N15/00
CPC分类号： C07K14/045 , C12N2710/16121
摘要： Provided are a full genome DNA of a human cytomegalovirus (HCMV) strain JHC isolated from Korean patients and open reading frames (ORFs) thereof and, more particularly, UL1, UL119 and RL6.
摘要翻译：提供从韩国患者和其开放阅读框（ORF）分离的人巨细胞病毒（HCMV）菌株JHC，更具体地，UL1，UL119和RL6分离的全基因组DNA。

3. 发明申请

US20130058897A1 HEXON ISOLATED FROM SIMIAN ADENOVIRUS SEROTYPE 19, HYPERVARIABLE REGION THEREOF AND CHIMERIC ADENOVIRUS USING THE SAME 审中-公开
公开(公告)号：US20130058897A1
公开(公告)日：2013-03-07
申请号：US13641027
申请日：2010-04-14
申请人： Kyuhyun Lee , Seongtae Yun , Daekyung Koh , Hong-Kyu Lee , Eui-Cheol Jo
发明人： Kyuhyun Lee , Seongtae Yun , Daekyung Koh , Hong-Kyu Lee , Eui-Cheol Jo
IPC分类号： A61K35/76 , C12N15/34 , C12N5/10 , C12N15/861 , A61P35/00 , C07K14/075 , C12N7/01
CPC分类号： C12N7/00 , A61K39/0011 , A61K2039/5256 , C07K14/005 , C12N15/86 , C12N2710/10321 , C12N2710/10322 , C12N2710/10332 , C12N2710/10342 , C12N2710/10343 , C12N2710/10345 , C12N2810/6018
摘要： Novel hexon isolated from simian adenovirus serotype 19 encoded in the polynucleotide defined as SEQ ID NO: 3, hepervariable region thereof, chimeric adenovirus comprising the same, and therapeutic use thereof provides a solution to the problem of safety and effective systemic treatment for developing gene therapeutic agents using adenovirus.

4. 发明授权

US07858361B2 Transformed Saccharomyces cerevisiae and method for mass-production of LK8 protein using the same 有权
标题翻译：转化的酿酒酵母以及使用该酵母的大量生产LK8蛋白的方法
公开(公告)号：US07858361B2
公开(公告)日：2010-12-28
申请号：US10587155
申请日：2005-01-26
申请人： Hyung-Kwon Lim , Jung Hwan Park , Sung-Geun Kim
发明人： Hyung-Kwon Lim , Jung Hwan Park , Sung-Geun Kim
IPC分类号： C12N1/00
CPC分类号： C12N15/81 , C07K14/755
摘要： The present invention relates to a method for preparing LK8 protein, more precisely, a method for mass-production of LK8 protein using Saccharomyces cerevisiae transformed by a gene coding LK8 protein having angiogenesis inhibiting activity. The transformed strain of the present invention and production processes of LK8 protein are expected to contribute greatly to the commercialization of LK8 protein as a novel angiogenesis inhibitor.
摘要翻译：本发明涉及一种用于制备LK8蛋白的方法，更确切地说，涉及使用由编码具有血管发生抑制活性的LK8蛋白的基因转化的酿酒酵母来批量生产LK8蛋白的方法。预期本发明的转化菌株和LK8蛋白的生产过程对于作为新型血管发生抑制剂的LK8蛋白质的商业化有很大贡献。

5. 发明授权

US07722887B1 Detoxified mutants of escherichia coli heat-labile enterotoxin 有权
标题翻译：大肠杆菌热不稳定肠毒素的解毒突变体
公开(公告)号：US07722887B1
公开(公告)日：2010-05-25
申请号：US10088202
申请日：1999-09-15
申请人： Eun Jeong Park , Jang Seong Kim , Jihoon Chang , Jungsun Yum , Soo-il Chung
发明人： Eun Jeong Park , Jang Seong Kim , Jihoon Chang , Jungsun Yum , Soo-il Chung
IPC分类号： A61K39/108 , A61K39/38 , A61K39/02 , A61K38/00
CPC分类号： C07K14/245 , A61K39/00
摘要： The present invention relates to detoxified and immunologically active proteins (“mutant LTs”) having mutated amino acid sequences of heat-labile enterotoxin of E. coli, DNA sequences encoding the mutant LTs, recombinant expression vectors comprising the DNAs, recombinant microorganisms transformed with the recombinant expression vectors, process for preparing the mutant LTs and pharmaceutical application of the said protein as immunogenic antigens for vaccination and as adjuvants for anti-body production. In contrast to wild-type LT, the mutant LTs did not induce any toxic activities. The mutant LTs elicited high and comparable levels of anti-LT antibodies when delivered either intragastrically or intranasally, inducing systemic and local responses in serum and fecal extracts. Thus, they might be useful for the development of a novel diarrheal vaccine in humans and animals. In addition, the antibody production ability using mutant LTs as an adjuvant may be effective for prevention and treatment of various diseases.
摘要翻译：本发明涉及具有大肠杆菌热不稳定肠毒素突变氨基酸序列的解毒和免疫活性蛋白（“突变LT”），编码突变LT的DNA序列，包含DNA的重组表达载体，用重组表达载体，用于制备突变LT的方法和所述蛋白质的药物应用作为用于疫苗接种的免疫原性抗原以及用于抗体产生的佐剂。与野生型LT相比，突变LT不诱导任何毒性活性。突变LTs在胃内或鼻内递送时引起高水平和相当水平的抗LT抗体，在血清和粪便提取物中诱导全身和局部反应。因此，它们可能对于在人和动物中发展新的腹泻疫苗是有用的。此外，使用突变型LTs作为佐剂的抗体生产能力可有效预防和治疗各种疾病。

6. 发明授权

US07422874B2 Expression vector for animal cell 有权
标题翻译：动物细胞表达载体
公开(公告)号：US07422874B2
公开(公告)日：2008-09-09
申请号：US10343303
申请日：2001-07-27
申请人： Jong-Mook Kim , Jung-Seob Kim , Sun-Mo Oh , Jae-Seung Yoon , Kwang-Hee Baek , Soo-Il Chung , Doo-Hong Park , Yeup Yoon
发明人： Jong-Mook Kim , Jung-Seob Kim , Sun-Mo Oh , Jae-Seung Yoon , Kwang-Hee Baek , Soo-Il Chung , Doo-Hong Park , Yeup Yoon
IPC分类号： C12N15/85 , C12N15/64 , C12P21/00
CPC分类号： C12N15/85 , C07K14/4717 , C07K14/595 , C07K14/71 , C12N2830/46
摘要： The present invention relates to an expression vector for animal cells. Specifically, the present invention relates to an expression vector, pMS vector, pSG vector and pMSG vector, including the human β-globin 5′ MAR complementary sequence or/and the transcription termination site of the gastrin gene. An expression system using an expression vector of the present invention can successfully produce recombinant proteins in various animals cells and recombinant protein having a unique structure and function.
摘要翻译：本发明涉及动物细胞的表达载体。具体地说，本发明涉及表达载体pMS载体，pSG载体和pMSG载体，包括人β-珠蛋白5'MAR互补序列或/和胃泌素基因的转录终止位点。使用本发明的表达载体的表达系统可以成功地在各种动物细胞中产生重组蛋白质，并具有独特的结构和功能的重组蛋白质。

7. 发明授权

US5985609A Process for preparing hepatitis C virus envelope glycoproteins 失效
标题翻译：制备丙型肝炎病毒包膜糖蛋白的方法
公开(公告)号：US5985609A
公开(公告)日：1999-11-16
申请号：US334545
申请日：1994-11-04
申请人： Mi-Kyung Min , Joon-Sang Park , Jung-Seob Kim , Yung-Dae Yun , Hong-Mo Moon
发明人： Mi-Kyung Min , Joon-Sang Park , Jung-Seob Kim , Yung-Dae Yun , Hong-Mo Moon
IPC分类号： A61K39/00 , C07K14/18 , C12N15/51 , C07H21/04 , C12Q1/70
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/24222
摘要： The present invention relates to a novel process for preparing hepatitis C virus (HCV) envelope glycoproteins employing Chinese Hamster Ovary (CHO) cells transformed with recombinant expression vectors containing the hepatitis C virus genome. The present invention provides CHO cells cotransfected with DHFR (dihydrofolate reductase) minigene pDCHIP and recombinant expression vectors containing cDNAs of HCV E1 and E2/NS1 ligated with tissue plasminogen activator signal sequence. HCV E1 and E2/NS1 envelope glycoproteins are produced in a massive manner from the transformed CHO cells adapted in methotrexate. The HCV envelope glycoproteins produced by the present invention can be applied to the development of a diagnostic reagent and a potential preventive HCV vaccine.
摘要翻译：本发明涉及使用含有丙型肝炎病毒基因组的重组表达载体转化的中国仓鼠卵巢（CHO）细胞制备丙型肝炎病毒（HCV）包膜糖蛋白的新方法。本发明提供了与DHFR（二氢叶酸还原酶）小基因pDCHIP共转染的CHO细胞和含有与组织纤溶酶原激活物信号序列连接的HCV E1和E2 / NS1的cDNA的重组表达载体。从适应于甲氨蝶呤的转化的CHO细胞以大量方式产生HCV E1和E2 / NS1包膜糖蛋白。由本发明生产的HCV包膜糖蛋白可用于开发诊断试剂和潜在的预防性HCV疫苗。

8. 发明申请

US20170145107A1 EPITOPES OF EPIDERMAL GROWTH FACTOR RECEPTOR SURFACE ANTIGEN AND USE THEREOF 审中-公开
公开(公告)号：US20170145107A1
公开(公告)日：2017-05-25
申请号：US15425413
申请日：2017-02-06
申请人： GREEN CROSS CORPORATION , MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
发明人： Se-Ho KIM , Kwang-Won HONG , Ki-Hwan CHANG , Min-soo KIM , Mi-jung LEE , Jong-hwa WON , Min-Kyu HUR , Hyun-Soo CHO , Ji-Ho YOO
IPC分类号： C07K16/30 , C12N15/10 , A61K39/00
CPC分类号： C07K16/3046 , A61K39/0005 , A61K39/0011 , A61K2039/53 , C07K16/2863 , C07K2317/10 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/567 , C07K2317/76 , C12N15/1037 , G01N33/57492 , G01N2333/71
摘要： Disclosed are epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-α, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.

9. 发明申请

US20150231220A1 EPITOPES OF EPIDERMAL GROWTH FACTOR RECEPTOR SURFACE ANTIGEN AND USE THEREOF 审中-公开
标题翻译：表皮生长因子受体表面抗原的抗原及其用途
公开(公告)号：US20150231220A1
公开(公告)日：2015-08-20
申请号：US14388665
申请日：2013-03-27
申请人： GREEN CROSS CORPORATION , MOGAN BIOTECHNOLOGY RESEARCH INSTITUTE
发明人： Se-Ho Kim , Kwang-Won Hong , Ki Hwan Chang , Min-soo Kim , Mi-Jung Lee , Jong-Hwa Won , Min-Kyu Hur , Hyun-Soo Cho , Ji-Ho Yoo
IPC分类号： A61K39/00 , G01N33/574 , C07K16/28
CPC分类号： C07K16/3046 , A61K39/0005 , A61K39/0011 , A61K2039/53 , C07K16/2863 , C07K2317/10 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/567 , C07K2317/76 , C12N15/1037 , G01N33/57492 , G01N2333/71
摘要： The present invention relates to epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes provided by the present invention are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-a, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.
摘要翻译：本发明涉及表皮生长因子受体（EGFR）的表位及其用途。由本发明提供的表位高度保留，并且位于与表皮生长因子（EGF）结合密切相关的结构域中。因此，包含表位或包含表位抗体的组合物的疫苗组合物可以有效地阻断由EGF和EGRF的结合引起的信号转导，因此可以高度有价值地用于治疗各种疾病如癌症。与本发明的表位结合的抗体可以有效地抑制EGFR等多种EGFR配体的结合，所述EGFR配体不仅具有EGFR，而且可以用于治疗各种EGFR，由于不仅与EGF结合而且与其他EGFR配体结合而引起的EGFR激活引起的疾病。

10. 发明授权

US09018182B2 Tumor specific promoter and oncolytic virus vector comprising the same 有权
标题翻译：肿瘤特异性启动子和包含其的溶瘤病毒载体
公开(公告)号：US09018182B2
公开(公告)日：2015-04-28
申请号：US13642962
申请日：2010-04-26
申请人： Daekyung Koh , Seongtae Yun , Kyuhyun Lee , Hong-Kyu Lee , Mihee Hwang , Chae-Ok Yun , Eui-Cheol Jo
发明人： Daekyung Koh , Seongtae Yun , Kyuhyun Lee , Hong-Kyu Lee , Mihee Hwang , Chae-Ok Yun , Eui-Cheol Jo
IPC分类号： C12N15/113 , A61K35/76
CPC分类号： A61K35/76 , A61K35/13 , A61K35/761 , C12N2830/008
摘要： Provided are tumor-specific promoters, oncolytic virus vectors and a pharmaceutical composition comprising the virus vector. The virus vector comprising the novel tumor-specific promoter shows excellent oncolytic effects on tumor cells, and thus it is useful for treating a cancer.
摘要翻译：提供肿瘤特异性启动子，溶瘤病毒载体和包含病毒载体的药物组合物。包含新型肿瘤特异性启动子的病毒载体对肿瘤细胞显示出优异的溶瘤作用，因此可用于治疗癌症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式